AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

IMMUTEP LIMITED Investor Presentation 2012

Oct 2, 2012

65122_rns_2012-10-02_fd5f74af-63e2-4f30-ac41-e5241998f81b.pdf

Investor Presentation

Open in viewer

Opens in your device viewer

==> picture [214 x 39] intentionally omitted <==

ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN:US74154B2034) 03 October 2012

PRIMA BIOMED TO PRESENT AT 3[RD] ANNUAL

“CANCER IMMUNOTHERAPY: A LONG-AWAITED REALITY” CONFERENCE

Prima BioMed Ltd (ASX:PRR; NASDAQ:PBMD; ISIN:US74154B2034) (“Prima,” the “Company”) announces that its CEO Matthew Lehman will present a corporate update at the 3[rd] annual “Cancer Immunotherapy: A Long-Awaited Reality” conference to be held at the New York Academy of Medicine in New York, NY (USA) on October 4, 2012.

Following the event, a video webcast of Prima's presentation will be available through the conference organizer website: www.regonline.com/mdb2012.

"Cancer Immunotherapy: A Long Awaited Reality" is a unique, single-day conference event that unites founding visionary researchers, clinicians, business leaders, key investors, and other stakeholders to engage in discussions, exchange information, highlight opportunities, and showcase leading companies in the field of cancer immunotherapy.

About Prima BioMed

Prima BioMed is a globally active biotechnology company headquartered in Australia. As a leader in personalized bio-therapeutic products for cancer, Prima is dedicated to leveraging its current technology and expertise to develop innovative treatment options for patients and maximize value to shareholders. Prima's lead product is CVac™, an autologous dendritic cell product currently in clinical trials for ovarian cancer patients who are in remission.

ENDS